People
Biom’up today announced the appointment of George Makhoul as Chief Commercial Officer with responsibility for the United States, effective today.
As January ends, biotech and pharma companies tap new leaders to help drive strategic visions. New hires at Histogen, Indalo, Novartis Oncology, Calico, and more.
Despite the significant amount of finances invested in the Bay Area biotech environment, December and January saw a significant number of job cuts.
Neos Therapeutics, Inc. announced the appointment of James Robinson to its board of directors.
Immunicum AB announced the composition of the Nomination Committee on 19 October 2018.
Lonza announced that Richard Ridinger, CEO, has decided to retire from the company after seven successful years.
Novartis Chief Executive Officer Vas Narasimhan said 2018 was a year of reimagining for Switzerland-based Novartis. It was a year when the company focused its capital and resourced on developing breakthrough medicines.
Singapore-based ASLAN slashed 30 percent of its staff following a recent mid-stage failure, and California-based Aduro has cut 37 percent of employees.
For 2018, Pfizer reported revenues of $53.6 billion, which was 2 percent operational growth. The fourth quarter brought in $14 billion, which was 5 percent operational growth.
As the trial against John Kapoor and other former executives at Insys Therapeutics continues, more sordid details of an aggressive campaign to boost sales of the company’s fentanyl-based sublingual spray for cancer pain are being brought to light.
PRESS RELEASES